News | July 23, 2021
Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Financial support is being provided as a grant from the Government of India
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Acquisition of A&C expands Aceto’s Western manufacturing footprint
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Subscribe To Our Newsletter & Stay Updated
